Dr. Hahn served as a consultant for Pear Therapeutics in 2022. All other authors declare no competing interests. This research was supported by the Fogarty International Center (D43 TW010543), the National Institute of Mental Health (R01MH114560), the National Institute of Allergy and Infectious Diseases (T32 AI007433), the National Heart, Lung, Blood Institute (K24 HL166024), and the National Institute on Alcohol Abuse and Alcoholism (K24 AA022586) of the National Institutes of Health.